A. 12q trisomy B. Del(17p) C. Lymphocyte count greater than 5000 µL D. CD5 positivity E. Unsure

A. Expression of the programmed cell death ligand (PD-L1) B. The cytogenetic abnormality t(9;22) C. Overexpression of cyclin D1 D. The cytogenetic abnormality del(13q) E. Unsure

A. Bortezomib B. Acalabrutinib C. Venetoclax D. Rituximab-hyperCVAD E. Unsure

A. Rituximab plus chlorambucil is equivalent to rituximab plus ibrutinib B. The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is superior to ibrutinib plus rituximab C. FCR is inferior to ibrutinib plus rituximab D. Acalabrutinib plus rituximab is superior to ibrutinib plus rituximab E. Unsure

A. Chlorambucil plus prednisone B. Rituximab C. Ibrutinib D. Ofatumumab E. Unsure

A. Ofatumumab B. Chlorambucil C. Acalabrutinib D. Fludarabine, cyclophosphamide, and rituximab E. Unsure

A. The dose of ibrutinib should be 420 mg by mouth daily B. JM is having his dentures fixed: ibrutinib should be held 7 days prior to his dental appointment C. Ibrutinib showed an approximately 2-fold increase in progression-free survival over temsirolimus D. The most common adverse event related to ibrutinib from the RAY study was hemorrhagic bleeding E. Unsure

A. Ibrutinib has no drug-drug interactions with warfarin and concurrent administration should present no risk B. Ibrutinib is associated with an increased risk of bleeding and should not be administered concurrently with warfarin C. Ibrutinib is associated with a decreased risk of bleeding and there is no harm in administering concurrently with warfarin D. Ibrutinib was found to prevent formation of blood clots and no other anticoagulation is needed E. Unsure

A. Nearly all patients will achieve a clinical response and, at 12 months, approximately two-thirds of patients will not have experienced disease progression B. The median overall survival is approximately 8 months C. Nearly all patients will achieve a clinical response; however, by 6 months, the majority of patients will have relapsed D. Approximately one-third of patients will achieve a clinical response and the duration of that response is 8 months at most E. Unsure

A. Acute hepatic failure, thromboembolism, and neuropathy B. Alopecia, mucositis, and severe nausea/vomiting C. Hemorrhage, myelosuppression, and atrial fibrillation D. Ileus, ototoxicity, and endocrinopathies E. Unsure